Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic
| Autor: | M Mandelikova, J. Klimes, K. Kruntoradova, T. Dolezal, T. Mlcoch |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Chemotherapy medicine.medical_specialty business.industry Health Policy medicine.medical_treatment Public Health Environmental and Occupational Health Follicular lymphoma Cost-effectiveness analysis CHOP medicine.disease law.invention Lymphoma Randomized controlled trial Drug control immune system diseases law hemic and lymphatic diseases Internal medicine medicine Rituximab business medicine.drug |
| Zdroj: | Value in Health. 17:A641 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2014.08.2314 |
| Popis: | [1] Rummel, MJ et al.: Bendamustin plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet 381, 1203-1210 (2013). [2] Expert panel conducted for the purposes of the model, available on request. [3] Salles, G. et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. The Lancet 377, 42-51 (2010). [4] Ray, JA et al. An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular NonHodgkin’s Lymphoma in the UK. Value in Health 13, 346-357 (2010). [5] Dewilde, S. et al.: Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin‘s lymphoma in England and Wales. Journal of Medical Economics 17, 111-124 (2014). [6] Czech National Bank. Average from the respective period (January-May 2014). Available online on [https://www.cnb.cz/cs/financni_trhy/devizovy_trh/ kurzy_devizoveho_trhu/prumerne_mena.jsp?mena=EUR] to 6th October 2014. [7] State Institute of Drug Control (SUKL) recommends, based on WHO recommendation, using 3-times GDP per capita as a willingness to pay threshold (see http://www.sukl.cz/file/73935_1_1/, translation available on request). On treatment* |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect